Skip to main content

Table 3 Adverse events

From: Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial

  Intervention (N = 149) Control (N = 75)
Participants (%) with adverse or serious adverse events 114 (77%) 47 (63%)
Number of adverse events (excluding serious events) 316 157
Participants (%) with serious adverse events 16 (11%) 12 (16%)
Number of serious adverse events 20 22
Participants with hypoglycemic serious adverse events 3 (2%) 1 (1%)
Number of hypoglycemic serious adverse events 3 1
Participants (%) with hypoglycemic adverse events 10 (7%) 7 (9%)
Number of hypoglycemic adverse events 27 30
Participants (%) with device-related adverse events 6 (4%) 0
Number of device-related adverse events 9* 0
Number of adverse events leading to discontinuation 1 3
Participants (%) discontinuing due to adverse events 1 (1%) 2 (3%)
  1. * All sensor adhesive reactions; 2 severe, 6 moderate, and 1 mild